Xin-Yuan Guan Selected Research

Cystadenoma

6/2010	Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma.
4/2010	Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma.
2/2009	Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
1/2005	Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xin-Yuan Guan Research Topics

Disease

154	Neoplasms (Cancer) 11/2022 - 04/2002
60	Hepatocellular Carcinoma (Hepatoma) 11/2022 - 08/2002
55	Neoplasm Metastasis (Metastasis) 11/2022 - 12/2003
26	Carcinogenesis 01/2020 - 12/2002
25	Esophageal Squamous Cell Carcinoma 10/2020 - 09/2009
19	Carcinoma (Carcinomatosis) 04/2022 - 12/2003
14	Nasopharyngeal Carcinoma 01/2021 - 04/2003
9	Liver Neoplasms (Liver Cancer) 01/2022 - 02/2008
9	Lymphatic Metastasis 01/2021 - 12/2003
7	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 12/2003
6	Breast Neoplasms (Breast Cancer) 01/2022 - 07/2004
6	Ovarian Neoplasms (Ovarian Cancer) 08/2013 - 12/2002
5	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2006
5	Melanoma (Melanoma, Malignant) 01/2022 - 02/2004
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 04/2014
5	Esophageal Neoplasms (Esophageal Cancer) 01/2021 - 03/2016
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2012 - 04/2005
4	Chromosomal Instability (Chromosome Stability) 01/2018 - 07/2005
4	Infections 04/2016 - 08/2002
4	Cystadenoma 06/2010 - 01/2005
3	Testicular Neoplasms (Testicular Cancer) 06/2022 - 05/2008
3	Residual Neoplasm 01/2021 - 07/2014
3	Hypoxia (Hypoxemia) 01/2021 - 06/2014
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018 - 01/2007
3	Genomic Instability 01/2017 - 08/2005
3	Adenoma (Adenomas) 01/2008 - 12/2003
2	Glioma (Gliomas) 11/2022 - 05/2014
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 04/2009
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 06/2010

Drug/Important Bio-Agent (IBA)

37	Proteins (Proteins, Gene)FDA Link 11/2022 - 04/2003
21	Biomarkers (Surrogate Marker)IBA 11/2022 - 02/2008
19	AgarIBA 11/2019 - 06/2004
16	RNA (Ribonucleic Acid)IBA 11/2022 - 05/2009
14	Pharmaceutical PreparationsIBA 01/2022 - 04/2003
14	MicroRNAs (MicroRNA)IBA 01/2020 - 12/2010
10	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 04/2003
10	DNA (Deoxyribonucleic Acid)IBA 11/2018 - 04/2002
8	Sorafenib (BAY 43-9006)FDA Link 06/2022 - 05/2016
8	CateninsIBA 01/2019 - 01/2011
8	Messenger RNA (mRNA)IBA 01/2019 - 08/2007
6	Phosphotransferases (Kinase)IBA 01/2022 - 12/2009
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2013
6	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2005
6	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2019 - 07/2009
6	Adenosine Triphosphatases (ATPase)IBA 01/2019 - 07/2009
6	Peptide Initiation Factors (Initiation Factor)IBA 01/2018 - 06/2004
6	eIF-5A2IBA 05/2011 - 06/2004
5	AntigensIBA 06/2022 - 01/2021
5	Cyclin D1IBA 12/2011 - 12/2009
4	CytokinesIBA 01/2022 - 01/2012
4	Carrier Proteins (Binding Protein)IBA 10/2021 - 08/2012
4	Histones (Histone)IBA 03/2021 - 04/2006
4	Matrix Metalloproteinases (MMPs)IBA 03/2021 - 04/2013
4	Long Noncoding RNAIBA 01/2021 - 01/2019
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 02/2016
4	EnzymesIBA 01/2020 - 02/2012
4	IntegrinsIBA 01/2019 - 11/2012
4	Neutralizing AntibodiesIBA 01/2018 - 03/2012
4	Conditioned Culture MediaIBA 01/2018 - 06/2009
4	ClusterinIBA 06/2010 - 01/2005
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
3	DNA HelicasesIBA 10/2021 - 09/2012
3	Biological ProductsIBA 01/2020 - 12/2002
3	Small Interfering RNA (siRNA)IBA 11/2019 - 02/2014
3	hepatitis B virus X proteinIBA 01/2019 - 02/2004
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 11/2017 - 04/2013
3	immune RNA (I-RNA)IBA 01/2017 - 08/2013
3	Cadherins (E-Cadherin)IBA 11/2014 - 04/2007
3	Complementary DNA (cDNA)IBA 01/2013 - 05/2008
3	NF-kappa B (NF-kB)IBA 01/2012 - 02/2004
3	Calcibiotic Root Canal SealerIBA 07/2005 - 12/2003
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 04/2022 - 06/2009
2	HMGB1 Protein (HMG1)IBA 01/2022 - 08/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 06/2014
2	LigandsIBA 01/2022 - 01/2020
2	CollagenIBA 03/2021 - 08/2014
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 10/2018
2	CalciumIBA 01/2021 - 11/2013
2	prenylIBA 12/2020 - 02/2009
2	Diphosphates (Pyrophosphates)IBA 12/2020 - 02/2009
2	Differentiation AntigensIBA 07/2020 - 08/2019
2	ChemokinesIBA 01/2020 - 01/2020
2	Amino Acids FDA Link 01/2020 - 04/2003
2	Neurofibromin 2 (Merlin)IBA 01/2019 - 01/2019
2	Cell Adhesion MoleculesIBA 01/2019 - 04/2007
2	Protein Isoforms (Isoforms)IBA 10/2018 - 08/2010
2	Insulin-Like PeptidesIBA 01/2018 - 01/2012
2	Tumor Biomarkers (Tumor Markers)IBA 01/2018 - 02/2008
2	16-iodo-3-methylhexadecanoic acid (MIHA)IBA 01/2018 - 08/2008
2	ChromatinIBA 05/2016 - 06/2014
2	Fibronectins (Fibronectin)IBA 04/2016 - 04/2010
2	Monoclonal AntibodiesIBA 07/2015 - 08/2002
2	Cyclin EIBA 03/2015 - 01/2012
2	Matrix Metalloproteinase 2 (Gelatinase A)IBA 08/2014 - 11/2011

Therapy/Procedure

25	Therapeutics 11/2022 - 07/2004
15	Drug Therapy (Chemotherapy) 01/2022 - 04/2003
5	Radiotherapy 01/2022 - 09/2007
5	Chemoradiotherapy 01/2020 - 09/2009
4	Immunotherapy 01/2022 - 01/2020
3	Lasers (Laser) 01/2022 - 05/2009